Leading Pharma Company Turns to Dendrite for High-Impact Business Intelligence and Cutting-Edge Sales Effectiveness Solutions.

BEDMINSTER, N.J. -- Company Capitalizes on Dendrite's Industry Expertise in Sales and Marketing Services to Enhance Effectiveness of Overall Sales Efforts

Dendrite International, Inc., (NASDAQ: DRTE) a leading provider of sales, marketing, clinical and compliance solutions for the life sciences industry, today announced that the US subsidiary of a leading global pharmaceutical company successfully implemented and rolled out an enhanced version of Dendrite's flagship WebForce(TM), a key component of Dendrite's First Source Sales Applications(TM) solution set, and Business Intelligence Data Mart (BIDM) solution that delivers immediate, high-impact business intelligence about brand, market and sales performance. Previously, this company had used an earlier version of WebForce(TM).

The company elected to expand its relationship with Dendrite following a rigorous review of products from competitors. The decision to expand the relationship with Dendrite was driven by Dendrite's strong, positive performance history working with the company, Dendrite's industry expertise and technical knowledge; and most importantly, the scalability of Dendrite's offerings, which were a critical consideration for this rapidly expanding company

With Dendrite's BIDM solution, this company marketing analysts can centrally manage and create reports based on large volumes of prescription data, managed care plans and customer phone calls located in different databases across the enterprise. The aggregated data derived from the solution, enables this company' sales representatives to gain comprehensive, accurate and actionable insights about their customers and their brands.

The implementation of WebForce provides the company with a robust set of customer relationship management capabilities that promote team selling, multi-channel customer management, information sharing, field reporting, and analytics. By integrating WebForce with the BIDM solution, Dendrite helps this company ensure its sales and marketing representatives are operating at maximum performance and efficiency. Dendrite also continues to provide a broad range of field force support services through its First Source Sales Support(TM) solution, including Help Desk Support, Hardware and Asset Management, training, and operational support for its applications.

"Our objective is to provide companies of all sizes with integrated sales and marketing solutions that substantially improve the efficiency of process for faster sales," said George Vargo, vice president, information technology at Dendrite. "Because of our deep domain expertise, we not only accomplish this, but also ensure that we give our customers the intelligence and the supporting technologies they need as a competitive advantage."

About Dendrite

Founded in 1986, Dendrite International (NASDAQ: DRTE) provides award-winning sales, marketing, clinical and compliance solutions and services to global pharmaceutical and other life sciences companies. With clients in more than 50 countries, including the world's top 20 pharmaceutical companies, Dendrite strives to be the first source for expert promotional and sales effectiveness solutions. For more information, please visit www.dendrite.com.

MEDIA INQUIRIES

Note: Dendrite is a registered trademark of Dendrite International, Inc.

This document may contain forward-looking statements that may be identified by such forward-looking terminology as "expect," "believe," "anticipate," "will," "intend," "plan," "target," "outlook," "guidance," and similar statements or variations. Such forward-looking statements are based on our current expectations, estimates, assumptions and projections and involve significant risks and uncertainties, including risks which may result from our dependence on the pharmaceutical industry; fluctuations in quarterly revenues due to lengthy sales and implementation cycles for certain of our solutions; our fixed expenses in relation to fluctuating revenues and variations in customers' budget cycles; dependence on certain major customers; changes in demand for our products and services attributable to any weakness experienced in the economy or mergers, acquisitions and consolidations in the pharmaceutical industry; successful and timely development and introduction of new products and versions; rapid technological changes; increased competition; international operations; integrating the entities we acquire; our ability to effectively manage our growth; the protection of our proprietary technology; our ability to compete in the Internet-related products and services market; the continued demand for Internet-related products and services; the ability of our third party vendors to respond to technological change; our ability to maintain our relationships with third-party vendors; less favorable than anticipated results from strategic relationships; dependence of data solutions on strategic relationships; events which may affect the U.S. and world economies; and catastrophic events which could negatively affect our information technology infrastructure. Other important factors that should be reviewed and carefully considered are included in the company's 10-K, 10-Qs, and other reports filed with the SEC. Actual results may differ materially. The company assumes no obligation for updating any such forward-looking statements to reflect actual results, changes in assumptions or other changes affecting such forward-looking statements.